Skip to main content

Peer Review reports

From: Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

Original Submission
25 May 2016 Submitted Original manuscript
5 Jun 2016 Author responded Author comments - Kouji Izumi
Resubmission - Version 2
5 Jun 2016 Submitted Manuscript version 2
1 Mar 2017 Reviewed Reviewer Report - Carsten-Henning Ohlmann
8 May 2017 Reviewed Reviewer Report - William Oh
8 May 2017 Reviewed Reviewer Report - Jun Luo
9 Jul 2017 Author responded Author comments - Kouji Izumi
Resubmission - Version 3
9 Jul 2017 Submitted Manuscript version 3
17 Jul 2017 Reviewed Reviewer Report - Carsten-Henning Ohlmann
3 Aug 2017 Reviewed Reviewer Report - William Oh
15 Sep 2017 Author responded Author comments - Kouji Izumi
Resubmission - Version 4
15 Sep 2017 Submitted Manuscript version 4
Publishing
28 Sep 2017 Editorially accepted
10 Oct 2017 Article published 10.1186/s12885-017-3661-2

You can find further information about peer review here.

Back to article page